Proven Track Record
Collectively, we have >100 publications, >25 composition of matter patents and two decades of drug discovery and translational science experience with a focus on delivering meaningful results.
Chemistry Group Leaders
Experienced drug discovery program leaders in diverse therapeutic areas including oncology, metabolism, rare-genetic disorders, anti-infectives (parasitic and antibacterial), lipid disorders and stroke.
Collaborate extensively with both academic investigators and biotech companies around the world to rapidly and efficient advance drug discovery projects toward key inflection points.
Dave co-founded Nexus Discovery Adivsors following a nine-year career at the NIH’s National Center for Advancing Translational Sciences (NCATS), where he was a Group Leader in Chemistry and co-led an interdisciplinary project team. NCATS was established to transform the translational science process so that new treatments and cures for disease can be delivered to patients faster. During his tenure at NCATS, Dave led a team of senior scientists in lead-identification and late-stage lead optimization efforts. He managed a project portfolio encompassing a broad range of therapeutic areas and target classes which involved close collaboration and interaction with leading researchers from around the world in both academia and the private sector. Most recently, he co-led a multi-center, NCI-funded drug discovery effort targeting an enzyme involved in cancer metabolism. Dave has co-authored over 75 scientific publications and is co-inventor on over 10 composition of matter patents. In addition, Dave has served as an ad hoc reviewer for the Defense Threat Reduction Agency (DTRA) and National Institute of Allergy and Infectious Diseases (NIAID) and frequently is invited to review scientific manuscripts. Dave earned a Bachelor of Science in Chemistry from the University of Vermont and a Doctor of Philosophy in Organic Chemistry from the University of Virginia. Following completion of his Ph.D., he was a Postdoctoral Fellow at Memorial Sloan-Kettering Cancer Center
Matt co-founded Nexus Discovery Advisors following a nine-year career at the NIH, most recently at NCATS, where he was Medicinal Chemistry Group Leader. At NCATS, he led interdisciplinary teams responsible for small molecule hit-to-lead and lead-optimization for over 25 projects across a wide range of diseases. His experience involved prosecuting targets in oncology, rare genetic disorders, infection and lipid disorders. Recently, Matt was project lead on a multi-institutional drug discovery project targeting an enzyme frequently mutated in cancer, and delivered a compound ready for investigational new drug (IND)-enabling studies. Also during his tenure, Matt collaborated with over 30 external investigators from academia, NIH, and the biotechnology sector. His collaborations have spanned across the United States and abroad. Matt is an inventor on over 10 patents, with multiple patents licensed by biotechnology companies. He frequently reviews for journals, grants, government and foundations with a focus on drug discovery. Matt earned a Bachelor of Science in Chemistry from the University of Vermont and a Ph.D. in Chemistry from the University of Chicago. He was a Postdoctoral Fellow at the NIH.